nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

10.04.2017 | Original Article

Sustained Placental Growth Factor-2 Treatment Does Not Aggravate Advanced Atherosclerosis in Ischemic Cardiomyopathy

verfasst von: Ming Wu, Peter Pokreisz, Melissa Swinnen, Ellen Caluwe, Hilde Gillijns, Nina Vanden Driessche, Andrea Casazza, Erik Verbeken, Desire Collen, Stefan Janssens

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Angiogenic growth factor therapy for ischemic cardiovascular disease carries a risk of stimulating atherosclerotic plaque growth. We evaluated risk benefit ratio of sustained administration of recombinant human placental growth factor (rhPlGF)-2 in mice with advanced atherosclerosis and chronic ischemic cardiomyopathy. We maintained apolipoprotein E-deficient mice on a high cholesterol diet and induced myocardial infarction by transient ligation at 4 weeks. At 8 weeks, we assessed left ventricular (LV) function and randomized mice to receive rhPlGF-2 or vehicle (VEH) subcutaneously for 28 days. Administration of rhPlGF-2 significantly increased PlGF plasma levels without adverse hemodynamic or systemic inflammatory effects. RhPlGF-2 did not increase plaque area, composition, or vulnerability in the aortic arch. RhPlGF-2 significantly improved contractile function and reduced LV end-systolic and end-diastolic volume indices with a concomitant increase in capillary and arteriolar density in ischemic myocardium. RhPlGF-2 may represent a promising therapeutic strategy in chronic ischemic cardiomyopathy.

Nur mit Berechtigung zugänglich

Giacca, M., & Zacchigna, S. (2012). VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Therapy, 19(6), 622–629. doi:10.1038/gt.2012.17.CrossRefPubMed

Sodha, N. R., Chu, L. M., Boodhwani, M., & Sellke, F. W. (2010). Pharmacotherapy for end-stage coronary artery disease. Expert Opinion on Pharmacotherapy, 11(2), 207–213. doi:10.1517/14656560903439737.CrossRefPubMedPubMedCentral

Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., et al. (2015). Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation, 131(4), e29–322. doi:10.1161/CIR.0000000000000152.CrossRefPubMed

Mack, C. A., Patel, S. R., Schwarz, E. A., Zanzonico, P., Hahn, R. T., Ilercil, A., et al. (1998). Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. The Journal of Thoracic and Cardiovascular Surgery, 115(1), 168–176. doi:10.1016/S0022-5223(98)70455-6.CrossRefPubMed

Rajanayagam, M. A., Shou, M., Thirumurti, V., Lazarous, D. F., Quyyumi, A. A., Goncalves, L., et al. (2000). Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. Journal of the American College of Cardiology, 35(2), 519–526. doi:10.1016/S0735-1097(99)00550-1.CrossRefPubMed

Lopez, J. J., Edelman, E. R., Stamler, A., Hibberd, M. G., Prasad, P., Caputo, R. P., et al. (1997). Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters. The Journal of Pharmacology and Experimental Therapeutics, 282(1), 385–390.PubMed

Harada, K., Grossman, W., Friedman, M., Edelman, E. R., Prasad, P. V., Keighley, C. S., et al. (1994). Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. The Journal of Clinical Investigation, 94(2), 623–630. doi:10.1172/JCI117378.CrossRefPubMedPubMedCentral

Lynch, P., Lee, T. C., Fallavollita, J. A., Canty Jr., J. M., & Suzuki, G. (2007). Intracoronary administration of AdvFGF-5 (fibroblast growth factor-5) ameliorates left ventricular dysfunction and prevents myocyte loss in swine with developing collaterals and ischemic cardiomyopathy. Circulation, 116(11 Suppl), I71–I76. doi:10.1161/CIRCULATIONAHA.106.681866.PubMed

Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., et al. (2003). The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation, 107(10), 1359–1365. doi:10.1161/01.CIR.0000061911.47710.8A.CrossRefPubMed

10.

Stewart, D. J., Hilton, J. D., Arnold, J. M., Gregoire, J., Rivard, A., Archer, S. L., et al. (2006). Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Therapy, 13(21), 1503–1511. doi:10.1038/sj.gt.3302802.CrossRefPubMed

11.

Losordo, D. W., Vale, P. R., Hendel, R. C., Milliken, C. E., Fortuin, F. D., Cummings, N., et al. (2002). Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation, 105(17), 2012–2018. doi:10.1161/01.CIR.0000015982.70785.B7.CrossRefPubMed

12.

Kastrup, J., Jorgensen, E., Ruck, A., Tagil, K., Glogar, D., Ruzyllo, W., et al. (2005). Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One trial. Journal of the American College of Cardiology, 45(7), 982–988. doi:10.1016/j.jacc.2004.12.068.CrossRefPubMed

13.

De Falco, S. (2012). The discovery of placenta growth factor and its biological activity. Experimental & Molecular Medicine, 44(1), 1–9. doi:10.3858/emm.2012.44.1.025.CrossRef

14.

Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., et al. (2002). Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Medicine, 8(8), 831–840. doi:10.1038/nm731.PubMed

15.

Dewerchin, M., & Carmeliet, P. (2012). PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harbor Perspectives in Medicine, 2(8). doi:10.1101/cshperspect.a011056.

16.

Hoffmann, D. C., Willenborg, S., Koch, M., Zwolanek, D., Muller, S., Becker, A. K., et al. (2013). Proteolytic processing regulates placental growth factor activities. The Journal of Biological Chemistry, 288(25), 17976–17989. doi:10.1074/jbc.M113.451831.CrossRefPubMedPubMedCentral

17.

Wu, M., Claus, P., Vanden Driessche, N., Reyns, G., Pokreisz, P., Gillijns, H., et al. (2016). Placental growth factor 2—a potential therapeutic strategy for chronic myocardial ischemia. International Journal of Cardiology, 203, 534–542. doi:10.1016/j.ijcard.2015.10.177.CrossRefPubMed

18.

Celletti, F. L., Waugh, J. M., Amabile, P. G., Brendolan, A., Hilfiker, P. R., & Dake, M. D. (2001). Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Medicine, 7(4), 425–429. doi:10.1038/86490.CrossRefPubMed

19.

Roncal, C., Buysschaert, I., Gerdes, N., Georgiadou, M., Ovchinnikova, O., Fischer, C., et al. (2010). Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovascular Research, 86(1), 29–36. doi:10.1093/cvr/cvp380.CrossRefPubMed

20.

Khurana, R., Moons, L., Shafi, S., Luttun, A., Collen, D., Martin, J. F., et al. (2005). Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation, 111(21), 2828–2836. doi:10.1161/circulationaha.104.495887.CrossRefPubMed

21.

Williams, R., Needles, A., Cherin, E., Zhou, Y. Q., Henkelman, R. M., Adamson, S. L., et al. (2007). Noninvasive ultrasonic measurement of regional and local pulse-wave velocity in mice. Ultrasound in Medicine & Biology, 33(9), 1368–1375. doi:10.1016/j.ultrasmedbio.2007.03.012.CrossRef

22.

Takagawa, J., Zhang, Y., Wong, M. L., Sievers, R. E., Kapasi, N. K., Wang, Y., et al. (2007). Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. Journal of Applied Physiology (1985), 102(6), 2104–2111. doi:10.1152/japplphysiol.00033.2007.CrossRef

23.

Dutta, P., Courties, G., Wei, Y., Leuschner, F., Gorbatov, R., Robbins, C. S., et al. (2012). Myocardial infarction accelerates atherosclerosis. Nature, 487(7407), 325–329. doi:10.1038/nature11260.CrossRefPubMedPubMedCentral

24.

Selvaraj, S. K., Giri, R. K., Perelman, N., Johnson, C., Malik, P., & Kalra, V. K. (2003). Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood, 102(4), 1515–1524. doi:10.1182/blood-2002-11-3423.CrossRefPubMed

25.

Kanwar, S. S., Stone, G. W., Singh, M., Virmani, R., Olin, J., Akasaka, T., et al. (2016). Acute coronary syndromes without coronary plaque rupture. Nature Reviews. Cardiology, 13(5), 257–265. doi:10.1038/nrcardio.2016.19.CrossRefPubMed

26.

Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L., & Ross, R. (1994). ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arteriosclerosis and Thrombosis, 14(1), 133–140.CrossRefPubMed

27.

Carnevale, D., Cifelli, G., Mascio, G., Madonna, M., Sbroggio, M., Perrino, C., et al. (2011). Placental growth factor regulates cardiac inflammation through the tissue inhibitor of metalloproteinases-3/tumor necrosis factor-alpha-converting enzyme axis: crucial role for adaptive cardiac remodeling during cardiac pressure overload. Circulation, 124(12), 1337–1350. doi:10.1161/CIRCULATIONAHA.111.050500.CrossRefPubMed

28.

Accornero, F., van Berlo, J. H., Benard, M. J., Lorenz, J. N., Carmeliet, P., & Molkentin, J. D. (2011). Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circulation Research, 109(3), 272–280. doi:10.1161/CIRCRESAHA.111.240820.CrossRefPubMed

29.

MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., et al. (2007). Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. The Journal of Clinical Investigation, 117(1), 153–164. doi:10.1172/JCI29154.CrossRefPubMedPubMedCentral

30.

Bishop, J. R., Schuksz, M., & Esko, J. D. (2007). Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature, 446(7139), 1030–1037. doi:10.1038/nature05817.CrossRefPubMed

31.

Tran-Lundmark, K., Tran, P. K., Paulsson-Berne, G., Friden, V., Soininen, R., Tryggvason, K., et al. (2008). Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circulation Research, 103(1), 43–52. doi:10.1161/circresaha.108.172833.CrossRefPubMedPubMedCentral

32.

Dallinga, M. G., & Dallinga-Thie, G. M. (2016). Role of sulfatase 2 in lipoprotein metabolism and angiogenesis. Current Opinion in Lipidology, 27(2), 181–186. doi:10.1097/MOL.0000000000000271.CrossRefPubMed

33.

Libby, P., & Pasterkamp, G. (2015). Requiem for the ‘vulnerable plaque’. European Heart Journal, 36(43), 2984–2987. doi:10.1093/eurheartj/ehv349.PubMed

34.

Autiero, M., Luttun, A., Tjwa, M., & Carmeliet, P. (2003). Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. Journal of Thrombosis and Haemostasis, 1(7), 1356–1370. doi:10.1046/j.1538-7836.2003.00263.x.CrossRefPubMed

35.

Cudmore, M. J., Hewett, P. W., Ahmad, S., Wang, K. Q., Cai, M., Al-Ani, B., et al. (2012). The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nature Communications, 3, 972. doi:10.1038/ncomms1977.CrossRefPubMed

36.

Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., et al. (2007). Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell, 131(3), 463–475. doi:10.1016/j.cell.2007.08.038.CrossRefPubMed

37.

Bellik, L., Vinci, M. C., Filippi, S., Ledda, F., & Parenti, A. (2005). Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia. British Journal of Pharmacology, 146(4), 568–575. doi:10.1038/sj.bjp.0706347.CrossRefPubMedPubMedCentral

38.

Schaper, W. (2009). Collateral circulation: past and present. Basic Research in Cardiology, 104(1), 5–21. doi:10.1007/s00395-008-0760-x.CrossRefPubMedPubMedCentral

Titel: Sustained Placental Growth Factor-2 Treatment Does Not Aggravate Advanced Atherosclerosis in Ischemic Cardiomyopathy
verfasst von: Ming Wu
Peter Pokreisz
Melissa Swinnen
Ellen Caluwe
Hilde Gillijns
Nina Vanden Driessche
Andrea Casazza
Erik Verbeken
Desire Collen
Stefan Janssens
Publikationsdatum: 10.04.2017
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 4/2017
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-017-9742-4

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Sustained Placental Growth Factor-2 Treatment Does Not Aggravate Advanced Atherosclerosis in Ischemic Cardiomyopathy

Abstract

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy

Exome Sequencing Identifies Candidate Genetic Modifiers of Syndromic and Familial Thoracic Aortic Aneurysm Severity

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)

A Swine Model of Percutaneous Intracoronary Ethanol Induced Acute Myocardial Infarction and Ischemic Mitral Regurgitation

The Notch Ligands DLL1 and Periostin Are Associated with Symptom Severity and Diastolic Function in Dilated Cardiomyopathy

Severity of Hypertension Correlates with Risk of Thromboembolic Stroke

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie